Literature DB >> 10843728

Autocrine and paracrine regulation by cytokines and growth factors in melanoma.

E Lázár-Molnár1, H Hegyesi, S Tóth, A Falus.   

Abstract

Tumour development and progression involves the expression of oncogenes and inactivation of tumour suppressor genes, leading to the appearance of multiple malignant characteristics. Malignant melanoma cells express different growth factors and cytokines and their receptors in respective stages of tumour progression, which by autocrine and paracrine effects enable them to grow autonomously and confer competence to metastasis. Autocrine growth factors (bFGF, MGSA/GRO, IL-8 and sometimes IL-6, PDGF-A, IL-10) produced by melanoma cells stimulate proliferation of the producing cell itself, while paracrine growth factors (for example PDGF, EGF, TGF-beta, IL-1, GM-CSF, IGF-I, NGF, VEGF) modulate the microenvironment to the benefit of tumour growth and invasion. Paracrine effects include angiogenesis, stroma formation, modulation of host immune response, activation of proteolytic enzymes, adhesion or motility and metastasis formation. Some growth factors have inhibitory effects on melanocytes and early lesions (IL-1, IL-6, TGF-beta, OSM, TNF and IFN) but not on advanced stage melanomas, and in some cases they switch to autocrine stimulator (IL-6, TGF-beta). Understanding the involvement of different growth factors and cytokines in the molecular mechanism of melanoma progression will help to provide an insight into new future therapeutic approaches for melanoma. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10843728     DOI: 10.1006/cyto.1999.0614

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  104 in total

1.  Interval sentinel lymph nodes in melanoma: a digital pathology analysis of Ki67 expression and microvascular density.

Authors:  Christian Marinaccio; Giuseppe Giudice; Eleonora Nacchiero; Fabio Robusto; Giuseppina Opinto; Gaetano Lastilla; Eugenio Maiorano; Domenico Ribatti
Journal:  Clin Exp Med       Date:  2015-08-15       Impact factor: 3.984

2.  Angiogenesis and melanoma - from basic science to clinical trials.

Authors:  Maxine Sylvia Emmett; Daemon Dewing; Rowan Oliver Pritchard-Jones
Journal:  Am J Cancer Res       Date:  2011-08-08       Impact factor: 6.166

3.  A novel FGF2 antagonist peptide P8 with potent antiproliferation activity.

Authors:  Lei Fan; Hang Xie; Lingzi Chen; Hui Ye; Shilong Ying; Cong Wang; Xiaoping Wu; Wulan Li; Jianzhang Wu; Guang Liang; Xiaokun Li
Journal:  Tumour Biol       Date:  2014-07-26

4.  Cross-talk between Dopachrome Tautomerase and Caveolin-1 Is Melanoma Cell Phenotype-specific and Potentially Involved in Tumor Progression.

Authors:  Ioana L Popa; Adina L Milac; Livia E Sima; Petruta R Alexandru; Florin Pastrama; Cristian V A Munteanu; Gabriela Negroiu
Journal:  J Biol Chem       Date:  2016-04-06       Impact factor: 5.157

5.  Macrophages in skin melanoma-the key element in melanomagenesis.

Authors:  Malgorzata Pieniazek; Rafal Matkowski; Piotr Donizy
Journal:  Oncol Lett       Date:  2018-02-09       Impact factor: 2.967

6.  Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.

Authors:  Michael G Gartside; Huaibin Chen; Omar A Ibrahimi; Sara A Byron; Amy V Curtis; Candice L Wellens; Ana Bengston; Laura M Yudt; Anna V Eliseenkova; Jinghong Ma; John A Curtin; Pilar Hyder; Ursula L Harper; Erica Riedesel; Graham J Mann; Jeffrey M Trent; Boris C Bastian; Paul S Meltzer; Moosa Mohammadi; Pamela M Pollock
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

7.  Immunohistochemical study of adenohypophysial cells during embryonic development in the reptile Chalcides chalcides (Squamata, Scincidae).

Authors:  Ida Ferrandino; Maria Consiglio Grimaldi
Journal:  J Mol Histol       Date:  2004-01       Impact factor: 2.611

8.  Phase II trial of vorinostat in advanced melanoma.

Authors:  N B Haas; I Quirt; S Hotte; E McWhirter; R Polintan; S Litwin; P D Adams; T McBryan; L Wang; L P Martin; M vonMehren; R K Alpaugh; J Zweibel; A Oza
Journal:  Invest New Drugs       Date:  2014-01-25       Impact factor: 3.850

9.  The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops.

Authors:  Una Adamcic; Karolina Skowronski; Craig Peters; Jodi Morrison; Brenda L Coomber
Journal:  Neoplasia       Date:  2012-07       Impact factor: 5.715

10.  Paracrine induction of endothelium by tumor exosomes.

Authors:  Joshua L Hood; Hua Pan; Gregory M Lanza; Samuel A Wickline
Journal:  Lab Invest       Date:  2009-09-28       Impact factor: 5.662

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.